Takeda and Amylin formally end rocky global alliance for obesity
Takeda and Amylin Pharmaceuticals have decided formally to end their October 2009 global agreement for the co-development and co-commercialization of compounds for obesity.
Takeda and Amylin Pharmaceuticals have decided formally to end their October 2009 global agreement for the co-development and co-commercialization of compounds for obesity.